Ra Pharmaceuticals (NASDAQ:RARX) Upgraded at BidaskClub

Ra Pharmaceuticals (NASDAQ:RARX) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Wednesday, June 26th, BidAskClub reports.

RARX has been the subject of a number of other reports. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 1,453 ($18.99) price target on shares of in a research report on Tuesday, June 18th. Robert W. Baird began coverage on shares of TAIWAN LIPOSOME/S in a research note on Thursday, June 20th. They set an “outperform” rating on the stock. Leerink Swann set a $5.00 price objective on shares of Tocagen and gave the stock a “hold” rating in a research note on Wednesday, May 22nd. Raymond James reduced their price objective on shares of Marathon Petroleum from $90.00 to $85.00 and set a “strong-buy” rating on the stock in a research note on Wednesday, April 10th. Finally, Zacks Investment Research upgraded shares of Eutelsat Communications from a “hold” rating to a “strong-buy” rating and set a $21.00 target price on the stock in a report on Wednesday, June 12th. One equities research analyst has rated the stock with a sell rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $37.73.

Ra Pharmaceuticals stock traded up $1.84 during midday trading on Wednesday, reaching $34.43. 332,796 shares of the company’s stock were exchanged, compared to its average volume of 452,042. Ra Pharmaceuticals has a 52 week low of $8.67 and a 52 week high of $34.50. The company has a current ratio of 20.10, a quick ratio of 20.10 and a debt-to-equity ratio of 0.02. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -16.71 and a beta of 1.23. The firm has a 50-day moving average price of $26.65.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.02. On average, sell-side analysts expect that Ra Pharmaceuticals will post -1.98 earnings per share for the current year.

In other news, insider Simon Read sold 10,000 shares of the company’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $22.25, for a total value of $222,500.00. Following the transaction, the insider now directly owns 8,521 shares in the company, valued at $189,592.25. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ramin Farzaneh-Far sold 10,595 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $33.10, for a total transaction of $350,694.50. Following the completion of the sale, the insider now owns 8,521 shares in the company, valued at $282,045.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,452 shares of company stock worth $640,963. 4.30% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in RARX. Sectoral Asset Management Inc grew its holdings in Ra Pharmaceuticals by 129.3% in the 4th quarter. Sectoral Asset Management Inc now owns 799,612 shares of the company’s stock worth $14,553,000 after acquiring an additional 450,900 shares during the last quarter. Spark Investment Management LLC bought a new stake in Ra Pharmaceuticals during the first quarter valued at approximately $3,458,000. Millennium Management LLC boosted its position in shares of Ra Pharmaceuticals by 407.0% in the fourth quarter. Millennium Management LLC now owns 412,066 shares of the company’s stock worth $7,500,000 after purchasing an additional 330,788 shares during the period. Emory University bought a new position in shares of Ra Pharmaceuticals in the fourth quarter worth approximately $2,714,000. Finally, Rhumbline Advisers boosted its position in shares of Ra Pharmaceuticals by 45.0% during the fourth quarter. Rhumbline Advisers now owns 20,725 shares of the company’s stock worth $377,000 after acquiring an additional 6,432 shares during the last quarter. 94.97% of the stock is currently owned by institutional investors.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Read More: What does a neutral rating on stocks mean?

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.